Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

Main Article Content

Diamant Thaci
Kenneth Gordon
Melinda Gooderham
Bruce Strober
Neil Korman
Subhashis Banerjee
Subhashis Banerjee
Elizabeth Colston
Jonghyeon Kim
John Throup
Akimichi Morita

Keywords

Deucravacitinib, JAK inhibitor, psoriasis, integrated laboratory parameter results, phase 3 trial

Abstract

N/A

References

1. Nogueira M et al. Drugs 2020;80:341-351.

2. Burke JR et al. Sci Transl Med 2019;11:1-16.

3. Armstrong A et al. Presented at the Annual Meeting of the American Academy of Dermatology; 2021

Most read articles by the same author(s)

<< < 1 2 3 4